Eli Lilly will be 'aggressive' in spending GLP-1 money, top dealmaker Van...
ORLANDO, Fla. — Eli Lilly’s new chief dealmaker is planning to spend its GLP-1 cash in an “aggressive” but responsible manner. Last month, Lilly’s president of oncology Jacob Van Naarden was
View Article#ASH25: Novartis says its antibody ianalumab helps prolong control of rare...
Novartis said its latest experimental approach for a rare blood disorder prolonged patients’ disease control by 45% compared to a placebo arm. The Phase 3 results, which follow a topline readout in ...
View Article#ASH25: Eli Lilly's Jaypirca makes first-line case, but ceiling may be capped
ORLANDO, Fla. — Fresh off an approval of Jaypirca last week in second-line leukemia patients, Eli Lilly is now looking to move up to the first-line setting with impressive data presented Tuesday. The...
View Article#SABCS25: BioNTech, BMS unwrap Phase 2 data for PD-L1xVEGF-A bispecific in...
BioNTech and Bristol Myers Squibb on Tuesday shared positive mid-stage breast cancer results for their PD-L1xVEGF-A bispecific antibody, which they claim has the potential to be a treatment backbone...
View ArticleRadial raises $50M to treat mental health in non-traditional ways
Radial, a startup pursuing newer ways to treat mental health using brain stimulation and fast-acting medications, just raised $50 million in Series A and seed funding, Endpoints News learned...
View ArticleSeven biotechs eye $2.3B in public offerings after data readouts
Investors can't seem to get enough of biotech stocks. On Monday evening and Tuesday morning, seven different biopharma companies announced plans to raise a total of $2.3 billion through stock sales,...
View ArticleStealthy biotech Sidera Bio raises $109M; Assembly's data for oral herpes drugs
Plus, news about Scancell Holdings, Immutep, Dr. Reddy's, Sensorion and Convergen: 💵 Sidera Bio reportedly gets $109M: Investors including Novo Holdings, Forbion, RA Capital Healthcare Fund and Gilde...
View ArticleEpilepsyGTx gets $33M to test epilepsy gene therapy in Phase 1/2a
After more than two years of pitching investors, a London upstart with two current employees has pulled through with a $33 million Series A to see if it can crack into a relatively niche pocket ...
View Article#ASH25: Early in vivo CAR-T results like Kelonia's elicit excitement across...
ORLANDO, Fla. — A single, ready-made infusion got rid of any detectable cancer cells in four multiple myeloma patients in Australia, Kelonia Therapeutics reported as part of its first clinical trial...
View ArticleNotes from the 2025 SABEW med tech fellowship
I’ve been paying more attention to wearable devices lately. HHS Secretary Robert F. Kennedy Jr. wants everyone to use one. I see more people wearing them. And wearables companies that ...
View ArticleNovartis to partner with AI-focused Relation on atopic diseases
Novartis has inked a deal with UK biotech Relation to discover and develop new drugs for certain immune diseases. This is the second deal with a large pharmaceutical company for Relation, which previously
View ArticleSanegeneBio raises $110M in follow-up to metabolic deal with Lilly
Just a month after announcing a deal with Eli Lilly to work on RNAi drugs for metabolic diseases, SanegeneBio has disclosed a $110 million Series B round to fund its work ...
View ArticleJ&J-backed Cellular Origins raises $40M for cell therapy manufacturing
UK-based cell therapy manufacturer Cellular Origins has raised $40 million in an over-subscribed Series A to expand to the US and secure more company partnerships. The round was led by Johnson &...
View Article#ASH25: New data from Gilead, J&J set up a bispecific, CAR-T rivalry
ORLANDO, Fla. — Clinical trials in multiple myeloma continue to rapidly progress, and nowhere was this more apparent than at the American Society of Hematology’s annual meeting. Companies like Johnson...
View ArticleFDA's probe of Covid-19 vaccines expands into adults
The FDA's investigation of Covid-19 vaccine safety in children has expanded into adults, according to people familiar with the agency's work — a significant widening of scope amid the Trump...
View ArticleEli Lilly earmarks $6B for GLP-1 pill factory in Alabama
Eli Lilly will spend $6 billion to build an orforglipron factory in Huntsville, AL, the third of four new US sites the pharma giant plans to announce this year. As well as manufacturing the oral ...
View ArticleFDA is taking another look at safety of approved RSV antibodies
The FDA is reexamining the safety of two approved RSV antibodies for infants, the latest move by the agency to scrutinize approved preventive products used in children. The FDA spoke with drugmakers...
View ArticleBlossomHill gets another $84M for macrocyclic approach to EGFR
With two cancer drugs in clinical testing, BlossomHill Therapeutics has convinced investors to fuel the San Diego startup with another $84 million in its attempt to take on AstraZeneca's EGFR inhibitor...
View ArticleD3 Bio raises $108M to take next-gen KRAS G12C drug into Phase 3
D3 Bio has secured $108 million in a Series B fundraise, with the main goal of advancing its lead drug candidate targeting KRAS-G12C into global registrational trials. The Shanghai-based biotech plans...
View ArticleUK lowers new medicine rebate scheme to 14.5% for 2026
The UK government's drug rebate tax will fall to 14.5% for new drugs next year, down from nearly 23%, according to new details following the UK-US trade deal revealed last week. But the payment rates ...
View Article